FY2025 · period end Dec '25 · from the 10-K filed Feb 20, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Gross Profit | $1.08B | $1.77B | $2.15B | $13.85B | $15.85B |
| Operating Income | negative: -$3.07B | negative: -$3.94B | negative: -$4.24B | $9.42B | $13.30B |
| Net Income | negative: -$2.82B | negative: -$3.56B | negative: -$4.71B | $8.36B | $12.20B |
| EPS (Diluted) | negative: -$7.26 | negative: -$9.28 | negative: -$12.33 | $20.12 | $28.29 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $12.34B | $14.14B | $18.43B | $25.86B | $24.67B |
| Total Liabilities | $3.69B | $3.24B | $4.57B | $6.74B | $10.52B |
| Stockholders' Equity | $8.65B | $10.90B | $13.85B | $19.12B | $14.14B |
| Cash & Equivalents | $2.60B | $1.93B | $2.91B | $3.21B | $6.85B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | negative: -$1.87B | negative: -$3.00B | negative: -$3.12B | $4.98B | $13.62B |
| Capital Expenditures | $0.19B | $1.05B | $0.71B | $0.40B | $0.28B |
| Free Cash Flow | negative: -$2.06B | negative: -$4.05B | negative: -$3.83B | $4.58B | $13.34B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 55.3% | 54.8% | 31.5% | 71.9% | 85.8% |
| Operating Margin | negative: -1.6% | negative: -1.2% | negative: -0.6% | 0.5% | 72.0% |
| Net Margin | negative: -1.5% | negative: -1.1% | negative: -0.7% | 0.4% | 66.1% |
| Return on Equity | negative: -28.9% | negative: -28.8% | negative: -28.6% | 50.3% | 86.3% |
| Return on Assets | negative: -21.3% | negative: -21.9% | negative: -21.3% | 33.1% | 49.5% |
| Debt / Equity | 0.07× | — | — | — | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001193125-26-408289 | Sep 30, 2026 | Sep 30, 2026 | Sep 30, 2026 11:15 UTC | EDGAR |
| 8-K | 0001193125-26-378505 | Aug 27, 2026 | Sep 1, 2026 | Sep 1, 2026 20:37 UTC | EDGAR |
| 10-Q | 0001682852-26-000150 | Jun 30, 2026 | Jul 31, 2026 | Jul 31, 2026 20:17 UTC | EDGAR |
| 8-K | 0001682852-26-000147 | Jul 31, 2026 | Jul 31, 2026 | Jul 31, 2026 11:03 UTC | EDGAR |
| 8-K | 0001682852-26-000134 | Jul 6, 2026 | Jul 8, 2026 | Jul 8, 2026 11:08 UTC | EDGAR |
| 8-K | 0001682852-26-000101 | May 6, 2026 | May 11, 2026 | May 11, 2026 10:06 UTC | EDGAR |
| 8-K | 0001682852-26-000057 | May 1, 2026 | May 1, 2026 | May 1, 2026 10:32 UTC | EDGAR |
| 10-Q | 0001682852-26-000060 | Mar 31, 2026 | May 1, 2026 | May 1, 2026 20:10 UTC | EDGAR |
Direct links to SEC EDGAR. MRNA has additional filings available on the SEC site.
6 numbers Moderna, Inc. later changed — same XBRL tag, both filings linked.
Net Income (Loss) Attributable to Parent·Q3 2016
Major restatementwas-$38K
Revised down in a 10-Q.
Stockholders' Equity Attributable to Parent·As of Dec 31, 2014
Major restatementwas-$4.4M
Revised up in a 10-K.
Liabilities·As of Dec 31, 2015
Major restatementwas$7.3M
Revised down in a 10-K.
Assets·As of Dec 31, 2015
Major restatementwas$7.6M
Revised down in a 10-K.
Operating Income (Loss)·Q1 2016
Major restatementwas-$1M
Revised up in a 10-Q.
Operating Income (Loss)·Q3 2016
Major restatementwas-$541K
Revised up in a 10-Q.
MRNA is not the only one.
See every restatement we've found across the market — or get an alert the next time MRNA revises a number.
Restatements are detected by comparing every vintage of a fact across all of Moderna, Inc.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows MRNA's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Moderna, Inc. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on MRNA yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on MRNA and publish the result to your public profile.
Ask about Moderna, Inc.
Continue in Workspace — cited answers on MRNA, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs